The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions.

Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na.sup.+, K.sup.+, Mg.sup.+, Cl.sup.−, and CH.sub.3COO.sup.− ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

In some embodiments provided herein is a method of treating a coagulopathy in a subject that is being administered or has been administered an antiplatelet agent, the method comprising: (a) determining that the subject has an abnormal result for evaluation of one or more clotting parameters; and (b) after (a), administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

There is provided a lipid mix composition comprising ionizable lipid, a structural lipid such as DSPC, a sterol, and a surfactant such as polysorbate 80, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, or D-α-Tocopherol polyethylene glycol 1000 succinate. The lipid mix compositions find particular use in transfecting difficult to transfect cells and maintaining the viability of those cells. The lipid mix compositions are particularly well suited to T cell transfection ex vivo.

The present invention relates to an AG-haESCs in which H19 DMR and IG-DMR are knocked out, a method for preparing the AG-haESCs, and use of the AG-haESCs in constructing a genetically modified semi-cloned animal and a library of a genetically modified semi-cloned animal. The AG-haESCs is capable of obtaining characteristics resembling a round spermatid, and upon injection into an oocyte, a viable SC mouse is stably obtained. The present invention is capable of being effectively used in multi-gene genetic manipulation, advancing the acquisition of animals with multiple genetic modifications.

The invention provides a microfluidic device comprising at least one cell culture chamber, the at least one cell culture chamber being connected to at least two openings, the device being configured to supply at least one physiologically active substance from at least one of the openings to the at least one cell culture chamber in such a manner as to form a concentration gradient or concentration gradients in the at least one chamber when cells and a hydrogel are introduced into the at least one cell culture chamber to culture the cells in a 3D-gel medium.

Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.

Described herein are methods and compositions for modifying a mammalian cell plasma membrane to retain secreted antibodies, capturing antibodies produced by the cells and sorting antibody producing cells according to antibody specificities or antibody quantities. These methods and compositions may be particularly useful for biological and medical applications. The methods may include modifying cell membranes from a population of antibody producing cells by inserting a membrane anchor into the cell membranes, a generic antibody capture molecule attached to the cell anchor, capturing antibodies produced by the cell, and detecting and dispending cells according to antibody specificities or antibody quantities with a microparticle sorting and dispensing apparatus.

Provided herein are methods of culturing NK-92® cells using the growth media containing a non-ionic surfactant such that the cell culture have reduced clumping as compared to control NK-92® cells that have been cultures in a control medium lacking the non-ionic surfactant. The growth medium comprises 0.025 to 0.9% of a non-ionic surfactant, e.g., Poloxamer 188.

The present invention relates to the purification of poloxamers to be used as cell culture media additives. Activated carbon can be used to remove hydrophobic high molecular weight components which reduce the efficacy of poloxamers as cell culture additives.